EFPIA：2025年创新药物不可用和延迟的根本原因：减少患者获得创新药物的时间报告摘要（英文版）

The unprecedented speed of innovation exhibited over the last five years and the promise of the industry pipeline provides an important opportunity to improve outcomes for patients • There is common agreement that the value of innovation is only realised when patients benefit from advances in treatment • However, a significant number of medicines are not available across all European Union (EU) markets • EFPIA has studied this through the W.A.I.T. Indicator Survey for many years and has asked CR